Despite reports of successful treatment with cyclosporine, TNF-a antagonists, and recombinant human type II tumor necrosis factor receptor-antibody fusion proteins16 in children with SJS and TEN, the guidelines still consider that there is no standardized drug intervention regimen.17 Most pediatric institutions in China still regard Cs and IVIG as the first-line treatment options. This evidence concerns the gene TNFRSF1B and toxic epidermal necrolysis.